A directory of the desks — the writers, the beats, the arguments in progress. Read in any order.
What began as a type-2 diabetes injectable is now a cultural, economic and clinical phenomenon. Our GLP-1 desk covers the trial data, the prescribing questions, the muscle-and-bone debates, and the long tail of patients who are not in any trial at all.
Enter the GLP-1 Desk →We are writing about a drug class that is older than most of its patients' exposure to it, and younger than most of its unanswered questions. — From the Editor's Note · April 2026
Ten years of published data, and the questions that matter most to the people on these drugs — muscle, bone, the hunger set point when you stop — are still unanswered.
The drug class that ate the endocrinology textbook, told one patient-year at a time.
The dual-agonist that is, on almost every measure, outperforming the monotherapy.
The drug that made the category, and is now trying to hold its lane.
The quiet, unglamorous layer of the market that most patients are actually on.
The next-generation molecules — retatrutide, survodutide, BPC-157, and the names you will hear by 2027.
The evidence, the grift, and the narrow strip of usefulness in between.
Continuous glucose monitors, mitochondrial biomarkers, and the slow reframing of what "metabolic" means outside the diabetes clinic.
The platforms, the pharmacies, and the policy that shape how patients actually access these drugs.
We add a desk when the beat earns it — meaning a story that doesn't fit anywhere else is showing up often enough to deserve its own editor. If you can see an argument we are missing, tell us.